Medical/Pharmaceuticals
Malaysian Society for Quality in Health (MSQH) Earns Global Recognition for its Organisational and Surveyor Training Programme Accreditation
KUALA LUMPUR, Malaysia, Jan. 14, 2025 /PRNewswire/ -- The Malaysian Society for Quality in Health (MSQH), a leading national healthcare accreditation body dedicated to ensuring the highest standards of quality and safety in healthcare services, proudly announces its successful re-certification fo...
2025-01-14 08:00
3578
Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference
MELBOURNE, Australia and INDIANAPOLIS, Jan. 14, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today advises that Dr.Christian Behrenbruch, Managing Director and Group CEO, will be presenting this week at the 43rd Annual J.P. Morgan Healthcare Confe...
2025-01-14 05:43
2488
MicroAire appoints Remco Maljers as Head of International Sales
CHARLOTTESVILLE, Va., Jan. 14, 2025 /PRNewswire/ -- MicroAire Surgical Instruments, a Marmon Holdings | Berkshire Hathaway company focused on plastic and upper extremity surgery, is pleased to announce the appointment ofRemco Maljers as its Head of International Sales. Remco brings with him exte...
2025-01-14 03:00
2306
BioCina and NovaCina Merger Bolsters Global CDMO Industry
ADELAIDE, South Australia and PERTH, Western Australia, Jan. 14, 2025 /PRNewswire/ -- Global Contract Development and Manufacturing Organizations (CDMOs) BioCina and NovaCina announced a strategic merger that will create a powerful brand in biopharmaceutical and small molecule contract manufactur...
2025-01-14 00:43
2910
Dx&Vx Presents a New Paradigm for Next-Generation Infectious Disease Response with the Development of a Universal Vaccine
- Preparing for Phase 2 Global Trials of a Ferritin Platform-Based Virus-Like Particle Universal Coronavirus Vaccine - Based on the Excellent Safety and Immune Response in Phase 1 Clinical Results, with a Plan to Extend Administration Routes and Indications SEOUL, South Korea, Jan. 13, 2025 /PRNe...
2025-01-13 22:00
3408
ZEISS MEL 90 excimer laser receives U.S. FDA approval; completes Corneal Refractive Workflow
The excimer laser complements the ZEISS VISUMAX 800 with ZEISS SMILE pro, extending ZEISS' LVC market leadership with treatment for myopia, hyperopia, and mixed astigmatism. DUBLIN, Calif. and JENA, Germany, Jan. 13, 2025 /PRNewswire/ -- ZEISS Medical Technology announced today that theMEL® 90 r...
2025-01-13 22:00
2498
CBC Group's R-Bridge Announces US$40M Synthetic Royalty-Backed Financing for Mirxes to Advance Global Expansion
- R-Bridge will provide bespoke financing of US$40 million with a synthetic royalty structure and flexible repayment terms - Financing will accelerate Mirxes, Singapore -based miRNA tech company's innovation and commercialization of cancer early detection solutions in new markets - Transacti...
2025-01-13 19:25
3251
XingImaging Opens State-of-the-Art Research Facility in New Haven, Connecticut
NEW HAVEN, Conn., Jan. 13, 2025 /PRNewswire/ -- XingImaging, a MITRO company, a leader in advanced research imaging and radiopharmaceutical services, is excited to announce the opening of its new state-of-the art research facility in New Haven, Connecticut. The facility includes a clinic to recrui...
2025-01-13 18:00
1710
Telix Exceeds FY24 Guidance with US$142M Q4 Revenue
MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today provides an update on its commercial and operational performance for the quarter ended31 December 2024 (Q4 2024). Sustained revenue growth * Q...
2025-01-13 15:12
3531
Scintimun® Commercialization Partnership with Curium Pharma
MELBOURNE, Australia and LIÈGE, Belgium, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has entered into an agreement with Curium Pharma for the transfer of marketing and distribution rights for Scintimun® (99m Tc-be...
2025-01-13 13:08
2336
Cornerstone Robotics Raises over US$70 million Funding to Forge Accessibility in Robotic Surgery
Funding from leading investors to accelerate R&D and international expansion to make robotic surgery solutions accessible to more HONG KONG, Jan. 13, 2025 /PRNewswire/ -- Cornerstone Robotics (the "Company"), a leading global innovator in surgical robotics, today announced that it has successful...
2025-01-13 09:05
3463
Cornerstone Robotics Raises over US$70 million Funding to Forge Accessibility in Robotic Surgery
Funding from leading investors to accelerate R&D and international expansion to make robotic surgery solutions accessible to more HONG KONG, Jan. 13, 2025 /PRNewswire/ -- Cornerstone Robotics (the "Company"), a leading global innovator in surgical robotics, today announced that it has successful...
2025-01-13 09:05
4934
Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has entered into an asset purchase agreement with antibody engineering company ImaginAb, Inc. (ImaginAb) to acquire a pipeline of next...
2025-01-13 06:34
3250
Duke-NUS marks 20 years with transformative S$30m in philanthropic gifts and pledges to boost next-gen medical breakthroughs
* The legacy of Duke-NUS' founding donor, the Estate of Khoo Teck Puat, continues with a transformativeS$5.5 million gift towards research. * The HEAD Foundation steps up with a S$200,000 scholarship, underpinning Duke-NUS' commitment to developing medical expertise. SINGAPORE, Jan. 11, 2025 ...
2025-01-11 22:15
4381
Kelun-Biotech Announce Exclusive License Agreement For SKB378/HBM9378, an Anti-thymic Stromal Lymphopoietin (TSLP) Monoclonal Antibody (mAb).
CHENGDU, China, Jan. 11, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company and HBM Holdings Limited ("Harbour BioMed") (together with the Company, the "Licensors"), have entered into an exclusive license agreement (the "License Agr...
2025-01-11 17:07
5173
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
* This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312) licensed a year ago and which advanced rapidly into the clinical phase. * Under the agreement, M...
2025-01-11 00:00
3836
JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma
SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the Center for Drug Evaluation (CDE) of the National Medical Products Adm...
2025-01-10 17:00
6230
Argon Medical Announces First Patient Enrollment in CLEAN-PE, a Prospective, Multicenter Study of a New Treatment for Pulmonary Embolism
PLANO, Texas, Jan. 9, 2025 /PRNewswire/ -- Argon Medical Devices, a leading provider of device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology procedures, announced the first patient enrollment in the CLEAN-PE study. The prospective, multicenter C...
2025-01-09 23:01
2738
UCB partners with Ailux Biologics, a Division of XtalPi, on Biologics AI Platform
* Computational advancements enable earlier and more widespread use of antibody-antigen structural insights across drug discovery process * These advancements have the potential to transform antibody discovery methods, broadening therapeutic applications and accelerating the development of in...
2025-01-09 16:41
3763
Samsung Biologics extends collaboration with LigaChem Biosciences for ADC development
* Samsung Biologics to offer ADC services at new dedicated facility * Extended collaboration reflects successful partnership and expertise INCHEON,South Korea, Jan. 9, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO),...
2025-01-09 09:45
3154
Week's Top Stories
Most Reposted
DBS is First Bank in Asia Pacific to Pilot Visa Intelligent Commerce for Everyday Payments
[Picked up by 321 media titles]
2026-02-16 10:00
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 316 media titles]
2026-02-19 14:30
Little Artists Art Studio, Singapore Shines at Art Capital 2026
[Picked up by 277 media titles]
2026-02-17 19:12
Tower Capital Asia announces majority investment in V-Key - a leader in digital identity and mobile application security
[Picked up by 265 media titles]
2026-02-13 01:52
Appier Delivers Record Results Driven by Agentic AI Innovation
[Picked up by 263 media titles]
2026-02-13 17:03Most Read
eufy Raises the Bar for Home Cleaning with Omni C28, Delivering One-Pass-Clean Performance with HydroJet™ Self-Clean Roller Mop
2026-02-14 10:00
7806
Cboe Launches Nearly 24-Hour Trading in Russell 2000 Index Options
2026-02-13 07:30
6882
Appier Delivers Record Results Driven by Agentic AI Innovation
2026-02-13 17:03
6522